Connect Sign In
3004572
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing
MEN2 NGS
Ordering Recommendation
Diagnostic and predictive testing for multiple endocrine neoplasia type 2 (MEN2) syndrome caused by pathogenic variants in the RET gene.
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-15 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect
Lavender or pink (EDTA) or yellow (ACD solution A or B).
Specimen Preparation
Transport 3 mL whole blood. (Min: 2 mL)
Storage/Transport Temperature
Unacceptable Conditions
Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.
Remarks
Stability
Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
Reference Interval
By report
Interpretive Data
Refer to report.
Compliance Category
Laboratory Developed Test (LDT)
Note
Gene Tested: RET (NM_020975)
Hotline History
Hotline History
Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
N/A
CPT Codes
81406
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3004573 | MEN2 Specimen | 31208-2 |
| 3004574 | MEN2 Interp |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
- familial medullary thyroid cancer (FMTC)
- MEN2A
- MEN2B
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing
Feedback
